|
|
NMT1 |
N-myristoyltransferase 1 |
- Late Phase of HIV Life Cycle
- Inactivation, recovery and regulation of the phototransduction cascade
- Activation, myristolyation of BID and translocation to mitochondria
|
- (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone
|
|
|
|
NMT2 |
N-myristoyltransferase 2 |
- Membrane binding and targetting of GAG proteins
- Inactivation, recovery and regulation of the phototransduction cascade
|
- Myristoyl-Coa
- S-(2-oxo)pentadecylcoa
- 1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL
- (Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE
|
|
|
|
NOP53 |
NOP53 ribosome biogenesis factor |
|
|
|
|
|
NPM1 |
nucleophosmin 1 |
- Nuclear import of Rev protein
- Nuclear import of Rev protein
- SUMOylation of transcription cofactors
- Deposition of new CENPA-containing nucleosomes at the centromere
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
|
|
|
|
|
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
- Regulation of ornithine decarboxylase (ODC)
|
- Menadione
- Dicoumarol
- Duroquinone
- 3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol
- ES-936
- Cibacron Blue
- Flavin adenine dinucleotide
- 5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione
- RH-1
- Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
- 3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE
- Cannabidiol
|
|
|
|
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
- Nuclear Receptor transcription pathway
|
|
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Circadian Clock
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
|
NR4A1 |
nuclear receptor subfamily 4 group A member 1 |
- AKT phosphorylates targets in the nucleus
- Nuclear Receptor transcription pathway
- Constitutive Signaling by AKT1 E17K in Cancer
|
|
|
|
|
NTHL1 |
nth like DNA glycosylase 1 |
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Displacement of DNA glycosylase by APEX1
- Defective NTHL1 substrate processing
- Defective NTHL1 substrate binding
|
|
|
|
|
OTUB1 |
OTU deubiquitinase, ubiquitin aldehyde binding 1 |
- Ub-specific processing proteases
- Ovarian tumor domain proteases
|
|
|
|
|
OTUD5 |
OTU deubiquitinase 5 |
- Ovarian tumor domain proteases
- Negative regulators of DDX58/IFIH1 signaling
|
|
|
|
|
PADI1 |
peptidyl arginine deiminase 1 |
- Chromatin modifying enzymes
|
|
|
|
|
PAFAH1B3 |
platelet activating factor acetylhydrolase 1b catalytic subunit 3 |
- COPI-independent Golgi-to-ER retrograde traffic
|
- (1R)-1,2,2-trimethylpropyl (R)-methylphosphinate
|
|
|
|
PARP1 |
poly(ADP-ribose) polymerase 1 |
- POLB-Dependent Long Patch Base Excision Repair
- vRNA Synthesis
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- Theophylline
- Zinc
- Carba-nicotinamide-adenine-dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- A-620223
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Talazoparib
- Niraparib
- Rucaparib
- Iniparib
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
|
PBK |
PDZ binding kinase |
|
|
|
|
|
PCDHA4 |
protocadherin alpha 4 |
|
|
|
|
|
PDGFRA |
platelet derived growth factor receptor alpha |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Imatinib-resistant PDGFR mutants
- Sunitinib-resistant PDGFR mutants
- Regorafenib-resistant PDGFR mutants
- Sorafenib-resistant PDGFR mutants
- PDGFR mutants bind TKIs
|
- Becaplermin
- Imatinib
- Sunitinib
- XL820
- Olaratumab
- Pazopanib
- Midostaurin
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Foreskin keratinocyte (neonatal)
- Fostamatinib
- Erdafitinib
- Amuvatinib
- Ripretinib
|
|
|
|
PDLIM7 |
PDZ and LIM domain 7 |
|
|
|
|
|
PELI1 |
pellino E3 ubiquitin protein ligase 1 |
- Regulation of necroptotic cell death
- Interleukin-1 signaling
- IRAK1 recruits IKK complex
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
|
|
|
PELI2 |
pellino E3 ubiquitin protein ligase family member 2 |
- Interleukin-1 signaling
- IRAK1 recruits IKK complex
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
|